Display:
Providers:
Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.
|
|
|
|
|
Yesterday's News, January 26, 2023 | ||
---|---|---|
January 24, 2023 | ||
January 20, 2023 | ||
January 19, 2023 | ||
January 04, 2023 | ||
December 22, 2022 | ||
Lilly and ProQR to Expand RNA Editing Collaboration(Globe Newswire) | ||
December 19, 2022 | ||
December 14, 2022 | ||
December 13, 2022 | ||
December 12, 2022 | ||
December 07, 2022 | ||
December 06, 2022 | ||
December 01, 2022 | ||
November 30, 2022 | ||
November 29, 2022 | ||
Next > |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2023. All rights reserved.